High incidence of secondary brain tumours after radiotherapy and antimetabolites

Lancet

Volumn 354, Issue 9172, 1999, Pages 34-39

  Relling, Mary V ^a,c   Rubnitz, Jeffrey E ^a,b   Rivera, Gaston K ^a,b   Boyett, James M ^a,b   Hancock, Michael L ^a,b   Felix, Carolyn A ^d   Kun, Larry E ^a,b   Walter, Andrew W ^a,b   Evans, William E ^a,b,c   Pui, Ching Hon ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMETABOLITE; CYTARABINE; HYDROCORTISONE; MERCAPTOPURINE; METHOTREXATE; TENIPOSIDE; THIOGUANOSINE; THIOPURINE METHYLTRANSFERASE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; BODY SURFACE; BRAIN TUMOR; CENTRAL NERVOUS SYSTEM TUMOR; CHILD; CONTROLLED STUDY; DRUG WITHDRAWAL; ERYTHROCYTE; GENETIC DISORDER; HIGH RISK PATIENT; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRATHECAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MOLECULAR BIOLOGY; ORAL DRUG ADMINISTRATION; PHENOTYPE; PRIORITY JOURNAL; RADIOTHERAPY; STATISTICAL ANALYSIS; TUMOR RECURRENCE;

EID: 0033519986     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)11079-6     Document Type: Article

References (35)

1. Rosso P., Terracini B., Fears T.R.et al. Second malignant tumors after elective end of therapy for a first cancer in childhood: a multicenter study in Italy. Int J Cancer. 59:1994;451-456.
2. Neglia J.P., Meadows A.T., Robison L.L.et al. Second neoplasms after acute lymphoblastic leukemia in childhood. N Engl J Med. 325:1991;1330-1336.
3. Hawkins M.M., Draper G.J., Kingston J.E. Incidence of second primary tumours among childhood cancer survivors. Br J Cancer. 56:1987;339-347.
4. Meadows A.T., Baum E., Fossati-Bellani F.et al. Second malignant neoplasms in children: an update from the late effects study group. J Clin Oncol. 3:1985;532-538.
5. Nygaard R., Garwicz S., Haldorsen T.et al. Second malignant neoplasms in patients treated for childhood leukemia. Acta Paediatr Scand. 80:1991;1220-1228.
6. Walter A.W., Hancock M.L., Pui C.H.et al. Secondary brain tumors in children treated for acute lymphoblastic leukemia at St Jude Children's Research Hospital. J Clin Oncol. 16:1998;3761-3767.
7. Elexpuru-Camiruaga J., Buxton N., Kandula V.et al. Susceptibility to astrocytoma and meningioma: influence of allelism at glutathione S-transferase (GSTT1 and GSTM1) and cytochrome P450 (CYP2D6) loci. Cancer Res. 55:1995;4237-4239.
8. Kuijten R.R., Strom S.S., Rorke L.B.et al. Family history of cancer and seizures in young children with brain tumors: a report from the Childrens Cancer Group (United States and Canada). Cancer Causes Control. 4:1993;455-464.
9. Evans W.E., Relling M.V., Rodman J.H., Crom W.R., Boyett J.M., Pui C.H. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med. 338:1998;499-505.
10. Evans W.E., Horner M., Chu Y.Q., Kalwinsky D., Roberts W.M. Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. J Pediatr. 119:1991;985-989.
11. Felix C.A., Nau M.M., Takahashi T.et al. Hereditary and acquired p53 mutations in childhood acute lymphoblastic leukemia. J Clin Invest. 89:1992;640-647.
12. Behm F.G., Raimondi S.C., Schell M.J., Look A.T., Rivera G.K., Pui C.H. Lack of CD45 antigen on blast cells in childhood acute lymphoblastic leukemia is associated with chromosomal hyperdiploidy and other favorable prognostic features. Blood. 79:1992;1011-1016.
13. Rubnitz J.E., Downing J.R., Pui C.H.et al. TEL gene rearrangement in acute lymphoblastic leukemia: a new genetic marker with prognostic significance. J Clin Oncol. 15:1997;1150-1157.
14. Gray R.J. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 16:1988;1141-1154.
15. Kalbfleisch, J.D., Prentice, R.L. The statistical analysis of failure time data. New York: John Wiley & Sons, 1980: 84-87.
16. Rubnitz J.E., Behm F.G., Pui C.H.et al. Genetic studies of childhood acute lymphoblastic leukemia with emphasis on p16, MLL, and ETV6 gene abnormalities: results of St Jude Total Therapy Study XII. Leukemia. 11:1997;1201-1206.
17. Chessells J.M., Bailey C.C., Richards S. MRC UKALL X: The UK protocol for childhood ALL, 1985-1990 - The Medical Research Council Working Party on Childhood Leukaemia. Leukemia. 6(2):1992;157-161.
18. Gelber R.D., Sallan S.E., Cohen H.J.et al. Central nervous system treatment in childhood acute lymphoblastic leukemia: long-term follow-up of patients diagnosed between 1973 and 1985. Cancer. 72:1993;261-270.
19. Weisburger E.K. Bioassay program for carcinogenic hazards of cancer chemotherapeutic agents. Cancer. 40:1977;1935-1949.
20. James S.J., Basknakian A.G., Miller B.J. In vitro folate deficiency induces deoxynucleotide pool imbalance, apoptosis, and mutagenesis in Chinese hamster ovary cells. Cancer Res. 54:1994;5075-5080.
21. Hiesse C., Kriaa F., Rieu P.et al. Incidence and type of malignancies occurring after renal transplantation in conventionally and cyclosporine-treated recipients: analysis of a 20-year period in 1600 patients. Transplant Proc. 27:1995;972-974.
22. Swenberg J.A. Chemical- and virus-induced brain tumors. Natl Cancer Inst Monogr. 46:1977;3-10.
23. 6-methylguanine and 6-thioguanine cytotoxic effects: a cross-resistant phenotype in N-methylnitrosourea-resistant Chinese hamster ovary cells. Cancer Res. 50:1990;4248-4253.
24. Volonte C., Ross A.H., Greene L.A. Association of a purine-analogue-sensitive protein kinase activity with p75 nerve growth factor receptors. Mol Biol Cell. 4:1993;71-78.
25. Sharif M. Mitogenic signaling by substance P and bombesin-like neuropeptide receptors in astrocytic/glial brain tumor-derived cell lines. Int J Oncol. 12:1998;273-286.
26. Elion G.B. The purine path to chemotherapy. Science. 24:1989;441-447.
27. Nelson W.G., Kastan M.B. DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol Cell Biol. 14:1994;1815-1823.
28. Modan B., Baidatz D., Mart H., Steinitz R., Levin S.G. Radiation-induced head and neck tumours. Lancet. i:1974;277-279.
29. Qin D., Ma J., Xiao J., Tang Z. Effect of brain irradiation on blood-CSF barrier permeability of chemotherapeutic agents. Am J Clin Oncol. 20:1997;263-265.
30. Fontana M., Stanton C., Pompili A.et al. Late multifocal gliomas in adolescents previously treated for acute lymphoblastic leukemia. Cancer. 60:1987;1510-1518.
31. Neuwelt E.A., Barnett P.A., Bigner D.D., Frenkel E.P. Effects of adrenal cortical steroids and osmotic blood-brain barrier opening on methotrexate delivery to gliomas in the rodent: the factor of the blood-brain barrier. Proc Natl Acad Sci USA. 79:1982;4420-4423.
32. Krynetski E.Y., Evans W.E. Pharmacogenetics of cancer therapy: getting personal. Am J Hum Genet. 63:1998;11-16.
33. Felix C.A., Slavc I., Dunn M.et al. p53 gene mutations in pediatric brain tumors. Med Pediatr Oncol. 25:1995;431-436.
34. Hollstein M., Sidransky D., Vogelstein B., Harris C.C. p53 mutations in human cancers. Science. 253:1991;49-53.
35. Kimball D.V., Gelber R.D., Li F., Donnelly M.J., Tarbell N.J., Sallan S.E. Second malignancies in patients treated for childhood acute lymphoblastic leukemia. J Clin Oncol. 16:1998;2848-2853.